Study of Muscle Energy Metabolism in RCC Patients Treated With Sunitinib

Fatigue Clinical Trial

Official title:

Evaluation of Technetium-99m Sestamibi to Determine Muscle Energy Metabolism in RCC (Renal Cell Cancer) Patients Treated With Sunitinib

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02428335
• Other study ID #: Sestamibi 1.0
• Status: Withdrawn
• Start date: June 2015
• Est. completion date: March 18, 2019

Study information

• Verified date: July 2019
• Source: AHS Cancer Control Alberta
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Sunitinib is a chemotherapy approved by the FDA as a standard of care treatment for renal cell carcinoma (RCC). Fatigue is a very common side effect of sunitinib that frequently causes dose reductions. The cause of this fatigue remains unclear. This study will use a special type of scan to study sunitinib-induced fatigue in relation to exercise.

Description:

Sunitinib, a type of tyrosine kinase inhibitor (TKI) has been approved by the FDA as a standard of care treatment for renal cell carcinoma (RCC). Fatigue is a very common side effect of sunitinib that frequently causes dose reductions. The cause of this fatigue remains unclear. It has been shown that TKIs disrupt growth factor pathways in muscles leading to muscle shrinkage. If sunitinib associated fatigue is due to altered muscle physiology at a molecular level, there will be observable changes in the uptake of 99mTc-sestamibi in scintigraphy scans. The study objective is to determine if sunitinib-induced fatigue as determined by VO2 and QOL fatigue related questionnaire responses are correlated to molecular changes in the muscles as evidenced by 99mTc-sestamibi uptake.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 18, 2019
• Est. primary completion date: March 18, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent before any study procedures completed

2. Patients must have histologically or cytologically confirmed RCC.

3. Four weeks must have elapsed since prior chemotherapy, hormonal therapy, targeted therapy or radiation therapy. There is no restriction on the amount of bone marrow previously radiated.

4. Recovery to baseline or, at most, grade 1 of all drug-related toxicities due to prior chemotherapy, radiation, hormonal therapy, or molecular targeted therapy, expect for alopecia.

5. Male / female subject = 18 years of age

6. Eastern Cooperative Oncology Group (ECOG) Performance Status of <2 (Karnofsky >70%)

7. Life expectancy of at least 12 weeks

8. Normal organ and marrow function as defined by :

• absolute neutrophil count (ANC) > 1500/mcL

• hemoglobin (Hb) > 90 g/L

• platelet count = 1000.000/mcL,

• total bilirubin = 1.5 x the upper limit of normal range (ULN)

• alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN (<5 x ULN presence of liver metastases)

• creatinine < 1.5 x institutional ULN

9. Cardiac ejection fraction by MUGA scan or echocardiogram must be >50% for patients at baseline.

10. Ability to understand the purpose of the study and the willingness to sign a written informed consent document

11. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment. Standard Nuclear Medicine department pregnancy screening will be conducted prior to each 99mTc-sestamibi scan. Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. The investigator is requested to advise the patient how to achieve an adequate contraception.

12. Patients must give written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.

Exclusion Criteria:

1. Patients who have had chemotherapy, hormonal therapy, molecular targeted therapy, or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.

2. Patients may not be receiving any other investigational agents, chemotherapy, immunotherapy, radiotherapy, or molecular targeted agents.

3. Prior treatment with a drug with known anti-angiogenic properties, including other tyrosine kinase inhibitors to VEGFR

4. Any psychological, familial, sociological, or geographical conditions that do not permit medical follow-up and compliance with the study protocol.

5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, HIV, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

6. Patients that are on therapeutic dose of coumadin or an INR of 1.5 c ULN. Patients that are on low dose coumadin (2mg or less for patency of the central venous catheter) or therapeutic dose of low molecular weight heparin will be allowed.

7. Patients who cannot swallow

8. Patients who are breast-feeding.

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Fatigue
• Renal Cell Cancer

Locations

Country	Name	City	State
Canada	Cross Cancer Institute	Edmonton	Alberta

Sponsors (1)

Lead Sponsor	Collaborator
AHS Cancer Control Alberta

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	99mTc-sestamibi uptake in muscle cells		12 weeks from start of treatment
Primary	99mTc-sestamibi uptake in muscle cells		24 weeks from start of treatment
Primary	99mTc-sestamibi uptake in muscle cells		36 weeks from start of treatment
Secondary	Incidence of sunitinib related fatigue		36 weeks after the start of sunitinib treatment